Investors

Financial reports and presentations

02 July 2020

Vaccibody doses first patient in Phase II clinical trial of VB10.16 in combination with immune-checkpoint inhibitor in advanced cervical cancer

Vaccibody doses first patient in VB C-02 study with VB10.16 plus atezolizumab (PDF).

Download
Warning: Undefined array key "HTTP_REFERER" in /var/www/0/351003/www/wp-content/themes/nykode-understrap-child/loop-templates/content-single-financial.php on line 67

Go back